ResearcherTaipei Veterans General HospitalNo recent work listed
Jack P. Wang
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 2
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper
Papers 3
- How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based stu… Co-author DOI 10.1186/s12904-016-0075-x↗
- Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Co-author DOI 10.18632/oncotarget.4216↗
- A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2239-1↗
Closest collaborators
The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chung‐Pin Li · 3 shared papers, 2013–2016 · strength 0.15
- Paper How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital … DOI 10.1186/s12904-016-0075-x↗
- Paper Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, … DOI 10.18632/oncotarget.4216↗
- Paper A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pan… DOI 10.1007/s00280-013-2239-1↗
- Yee Chao · 2 shared papers, 2013–2015 · strength 0.09
- Paper Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, … DOI 10.18632/oncotarget.4216↗
- Paper A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pan… DOI 10.1007/s00280-013-2239-1↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.